[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rosacea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rosacea":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,82,105,130,154,185,205,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100638035","transcutaneous-auricular-vagus-nerve-stimulation-treatment-for-rosacea-100638035",false,"NCT07600424","Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea","Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea: A Pilot Trial","Inclusion Criteria:\n\n* Adults aged 18 years of age and older\n* Dermatologist confirmed diagnosis of rosacea\n* Clinician's Erythema Assessment of at least 3 (moderate to severe disease)\n* Willingness to adhere to current rosacea regimen without additions or laser treatments (e.g. PDL) during the study period.\n\nExclusion Criteria:\n\n* Changes to rosacea regimen (prescription topical or oral medications) within 4 weeks of randomization.\n* Facial hair, tattoos, or other characteristics that would interfere with erythema assessments\n* History of symptomatic cardiac arrythmias (e.g. heart block, sick sinus syndrome, bradyarrhythmia)\n* Presence of a pacemaker, implanted defibrillator, or neurostimulator\n* Seizure disorder or epilepsy\n* Trigeminal Neuralgia within the past year\n* Severe coronary disease or recent myocardial infarction within the past 5 years\n* Severe autonomic dysfunction (e.g., frequent syncope, hospitalization)\n* History of recurrent syncope or unexplained fainting\n* Use of brimonidine or oxymetazoline within the past 4 weeks\n* Use of beta-blockers, anticholinergics, or vagal-modulating drugs within the past 4 weeks\n* Severe phymatous rosacea\n* Ear deformity, piercings, or other condition that prevents the use of the taVNS device\n* Known hypersensitivity to electrode materials\n* Patients who are pregnant.","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","A single arm, pilot study among individuals with rosacea and at least moderate flushing or rednesss will be enrolled in a 4-week trial of taVNS. The particicpants will be followed for an additional 4-weeks following the intervention period to evaluate the durability of the results",[26,27,28],"Rosacea","Rosacea, Erythematotelangiectatic","Flushing","NOT_YET_RECRUITING","2026-05-20",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":20},"2026-06-01",{"date":37,"type":20},"2028-02-28",{"name":39,"class":40},"Brigham and Women's Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":41},"100619166","skin-inflammation-in-perimenopause-a-probiotic-intervention-proof-of-concept-trial-100619166","NCT07341087","Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial","Skin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial (SIPPI)","SIPPI","Inclusion Criteria:\n\n1. Female, aged 40-60 years.\n2. Self-reported or clinician-diagnosed non-infectious, non-autoimmune inflammatory skin condition affecting the face (e.g., rosacea, acne, eczema).\n3. Willing and able to consume a daily oral intervention (2x 65 ml probiotic drinks or skimmed milk) for 8 weeks.\n4. Willing and able to provide sufficient blood, skin and stool samples at baseline and end-of-study (Week 8). Participants unable to provide adequate blood sample volumes will not be able to start the intervention.\n5. Willing and able to provide a photograph of the facial area, with all images anonymised for study purposes.\n6. Able to comply with study procedures, including attending clinic visits at KCL.\n7. Have access to a refrigerator at home and be able to store the study product(s) safely after collection (i.e., travel time allows safe storage).\n8. Capable of providing written informed consent.\n9. Have sufficient proficiency in English to complete study questionnaires and assessments.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to provide informed consent.\n2. Inability or unwillingness to comply with study protocol requirements (e.g., clinic visits, sample provision, daily consumption of study drink)\n3. Unwilling to record dietary intakes using handwritten diet diaries\n4. Not fluent in the English language\n5. Is planning on international travel during the study period\n6. Current participation in another interventional clinical trial or having received an investigational\u002Fpharmaceutical product within the past 3 months.\n7. Known allergy or intolerance to dairy products, skimmed milk, or probiotic drinks containing Lactobacillus species.\n8. Currently pregnant, currently breastfeeding or planning to become pregnant in the next 4 months.\n9. BMI \\\u003C18.5kg\u002Fm2 or \\> 35kg\u002Fm2.\n10. Unintentional weight loss greater than 4 kg in the 3 months prior to enrolment.\n11. History of substance abuse or alcoholism (alcohol intake \\>50 units\u002Fweek) within the last 12 months.\n12. Current smokers, or individuals who quit smoking in the last 6-months.\n13. Fasting glucose \\>7mmol\u002Fl (finger prick test at baseline clinic).\n14. Active skin infection requiring systemic antibiotics, antivirals, or antifungals within the past 4 weeks.\n15. Major gastrointestinal disease (e.g., inflammatory bowel disease, celiac disease, short bowel syndrome) or history of significant gastrointestinal surgery (excluding appendectomy or cholecystectomy).\n16. Known immunodeficiency (e.g., HIV, immunosuppressive therapy, systemic corticosteroids \\>10 mg\u002Fday prednisolone equivalent).\n17. History of malignancy or clinically significant non-malignant skin conditions within the past 5 years (except adequately treated basal cell carcinoma).\n18. Serious medical conditions that, in the opinion of the investigator, would compromise safety or interfere with study outcomes (e.g., uncontrolled diabetes, advanced cardiovascular, hepatic, or renal disease, active cancer, autoimmune conditions).\n19. Women with a history of severe psychiatric illness that would limit adherence to study requirements.\n20. Current use of probiotics, prebiotics, or antibiotics within 4 weeks prior to baseline.\n21. Current use of systemic corticosteroids, or other immunosuppressive\u002Fimmunomodulatory therapies within the past 3 months.\n22. Currently receiving, or having received, phototherapy (e.g., UVB, PUVA, laser\u002Flight-based treatments, including at home treatments) for any skin condition within the past 3 months.\n23. Currently receiving, or having received, systemic dermatology treatments likely to affect skin inflammation or immune response within the past 3 months (e.g., isotretinoin, methotrexate, cyclosporine, biologics such as TNF, IL-17, IL-23 or IL-4\u002FIL-13 inhibitors).\n24. Currently receiving, or having received, topical treatments likely to significantly alter skin inflammation within the past 3 months (e.g., high-potency topical corticosteroids, topical calcineurin inhibitors such as tacrolimus or pimecrolimus, topical retinoids, or photodynamic therapy).\n25. Currently using, or have used, probiotic skincare (e.g., topical creams and serums) within the past 3 months.\n26. Currently receiving, have undergone, or plan to undergo cosmetic skin procedures (e.g., chemical peels, laser therapy, dermal fillers, microneedling) within the 3 months prior to, or within 3 months after the first (baseline) visit.\n27. Currently using, or have used, hormonal contraceptives or treatments known to exacerbate skin conditions, including Mirena (levonorgestrel-releasing intrauterine system), oral progesterone-only contraceptives (e.g., mini-pill), and synthetic progestogens (e.g., norethisterone) within the past 3 months.","FEMALE","40 Years","60 Years",{"count":54,"type":20},30,[23],"This study will explore whether a daily probiotic drink containing Lactobacillus casei Shirota (LcS) can help improve immune function and reduce inflammation in women going through the menopausal transition. Hormonal changes during this stage of life can affect the immune system, gut health, and skin, sometimes leading to increased inflammation or conditions such as eczema, acne or rosacea.\n\nParticipants will consume either a low-sugar LcS probiotic drink or a skimmed milk control drink every day for eight weeks. The study will assess markers of immune ageing, inflammation, skin health, wellbeing, and hormone levels. The results will help determine whether a safe, non-hormonal probiotic approach may support immune and skin health during the menopausal transition.",[58,59,60,61,62,26,63,64],"Skin Inflammation","Immunosenescence","Inflammation","Skin Health","Eczema","Acne","Menopause",[66,67,68,69,70,71],"Probiotics","Lactobacillus casei Shirota","Immune ageing","Gut-skin axis","Skin health","Menopausal transition","RECRUITING","2026-05-05",{"date":75,"type":33},"2026-05-08",{"date":77,"type":33},"2026-04-28",{"date":79,"type":20},"2027-11-01",{"name":81,"class":40},"King's College London",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":41},"100540128","phase-2-evaluating-use-of-topical-imipramine-and-amitriptyline-in-reducing-ultraviolet-b-light-induced-redness-in-patients-with-rosacea-100540128","NCT06312813","Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea","Pilot Studies Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea","Inclusion Criteria:\n\n* Fitzpatrick Skin Type I - IIII\n* Self-identified rosacea or no history of flushing\u002Fblushing for controls\n* Able to provide medical history and list of medications -- control subjects will not be allowed to take medications that are known to be photosensitizers.\n\nExclusion Criteria:\n\n* Using imipramine, amitriptyline or any other tricyclic antidepressant (oral or topical)\n* Using topical anti-inflammatory (within 1 week) or systemic agents (e.g. prednisone)\n* Large tattoos in the designated testing areas\n* Tanning bed use within last 3 months\n* Photodynamic Therapy or UCB treatments in past 3 months\n* Female Subjects: pregnant or nursing",true,{"count":91,"type":20},48,[93],"PHASE2","Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.",[26],"2026-02-17",{"date":98,"type":33},"2026-02-18",{"date":100,"type":33},"2024-02-27",{"date":102,"type":20},"2028-12-01",{"name":104,"class":40},"Wright State University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":41},"100615737","acupuncture-for-refractory-rosacea-a-study-on-its-effectiveness-and-safety-100615737","NCT07296497","Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety","A Randomized, Multicenter, Single-blind, Sham-controlled Clinical Trial on the Efficacy and Safety of Acupuncture in the Treatment of Refractory Rosacea.","Inclusion Criteria:\n\n1. Patients diagnosed with refractory rosacea, defined as those who have received at least 12 weeks of conventional oral medication (such as doxycycline), with or without other treatments (e.g., topical medications or intense pulsed light \\[IPL\\] therapy), but remain treatment-resistant - characterized by no improvement of erythema by at least one CEA grade, persistent erythema ≥ grade 3, or recurrent flushing that affects quality of life (DLQI indicating at least a moderate impact); or patients who experience frequent relapses during the 12-week treatment period;\n2. Age between 18 and 65 years, inclusive, with no restriction on sex;\n3. Individuals who fully understand the purpose and significance of the study, voluntarily agree to participate, sign the informed consent form (ICF), and are willing to comply with all study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n1. Women who are pregnant, breastfeeding, or planning to become pregnant in the near future;\n2. Patients with diabetes mellitus or moderate to severe systemic diseases affecting the liver, kidney, lung, or hematologic system;\n3. Patients with depression or other psychiatric disorders;\n4. Individuals with severe abnormal reactions to acupuncture (e.g., syncope during acupuncture, allergy to acupuncture needles);\n5. Patients with rosacea accompanied by nasal hypertrophy or other facial dermatoses (such as seborrheic dermatitis, eczema) or facial manifestations of other systemic diseases (such as dermatomyositis, systemic lupus erythematosus);\n6. Individuals with a bleeding tendency or coagulation disorders, or with skin damage, infection, or other lesions at the acupuncture sites;\n7. Patients who discontinued oral antibiotics less than 1 month prior to enrollment; discontinued non-antibiotic oral medications less than 15 days prior (or isotretinoin less than 3 months prior); or discontinued topical medications less than 1 week prior;\n8. Patients who are expected to be unable to comply with follow-up requirements;\n9. Individuals who have participated in any other clinical trial within 1 month before screening (defined as having signed an informed consent form and received an investigational drug\u002Fdevice\u002Fplacebo);\n10. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.","65 Years",{"count":114,"type":20},104,[23],"This study is a randomized, multicenter, sham-controlled clinical trial designed to evaluate the efficacy and safety of acupuncture for patients with refractory rosacea. A total of 104 participants will be enrolled and randomly assigned in a 1:1 ratio to the acupuncture group or the sham acupuncture group (52 participants in each group, regardless of sex). The primary aim is to determine whether acupuncture can effectively alleviate facial erythema and flushing episodes compared with sham stimulation.",[26],[119,120],"rosacea","acupuncture","2026-01-28",{"date":123,"type":33},"2026-01-30",{"date":125,"type":33},"2025-12-24",{"date":127,"type":20},"2027-04-30",{"name":129,"class":40},"Xiangya Hospital of Central South University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":89,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100615270","vbeam-pro-pulse-dye-laser-for-the-treatment-of-vascular-conditions-100615270","NCT07290426","Vbeam Pro Pulse Dye Laser for the Treatment of Vascular Conditions","A Prospective Clinical Study Evaluating Pulse Dye Laser on Clearance of Vascular Indications","Inclusion Criteria:\n\n1. Healthy subjects aged 18 years or older\n2. Presence of one or more vascular lesion, cutaneous lesion, or other dermatological condition deemed fit for treatment\n3. Able and willing to comply with the treatment\u002Ffollow-up schedule and comply with all study (protocol) requirements.\n4. Willing to provide signed, informed consent to participate in the study\n5. Willing to have photographs and images taken of the treated areas to be used in evaluations, publications, presentations, and marketing materials\n\nExclusion Criteria:\n\n1. Pregnant or planning to become pregnant, having given birth less than 3 months prior to enrollment into the study, and\u002For breast feeding\n2. Known photosensitivity to 595nm or 1064 nm light\n3. History of light-induced seizure disorders\n4. Severe unstable concurrent conditions, such as unstable cardiac disorders\n5. Use of implanted medical device including pacemakers, cardioverters and other implantable devices or fillers per investigator discretion (consultation with physicians prior to treatment is required)\n6. Use of photosensitizing medications (medications that introduce photosensitivity or medications within or above the 595 nm wavelength, refer to Candela's list of drugs that may cause photosensitivity)\n7. Tattoos (including decorative, permanent makeup and radiation port tattoos) in the intended study treatment area (595nm use only)\n8. Active Herpes Simplex Virus (HSV) in the intended treatment area unless treated with prophylactic medication\n9. The intended treatment area has significant sun exposure within the past 2 weeks or self-tanner has been applied to the treatment area\n10. In the opinion of the Investigator, the subject is unwilling or unable to adhere to the study requirements or is otherwise unsuitable for the study",{"count":138,"type":20},40,[23],"This is a clinical study to evaluate the safety and performance of the Vbeam Pro Laser System for the treatment of vascular indications, including rosacea and port wine stain birthmarks.",[26,142,143],"Vascular Diseases","Port-Wine Stain","2025-12-16",{"date":146,"type":33},"2025-12-18",{"date":148,"type":20},"2026-03",{"date":150,"type":20},"2028-12",{"name":152,"class":153},"Candela Corporation","INDUSTRY",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":89,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":174,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":41},"100510571","determinants-of-chronic-inflammatory-skin-disease-trajectories-100510571","NCT05928169","Determinants of Chronic Inflammatory Skin Disease Trajectories","Inclusion Criteria:\n\n* dermatologist-diagnosed inflammatory skin disease\n* informed consent\n\nExclusion Criteria:\n\n* subject and\u002For the legal guardians are not able to give written informed consent\n* pregnant and breastfeeding women\n* concurrent participation in a clinical trial\n* use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months\n* treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection","0 Years","80 Years",{"count":163,"type":20},1000,"OBSERVATIONAL","Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.",[167,168,169,170,171,172,173,26],"Atopic Dermatitis","Psoriasis","Lichen Planus","Alopecia Areata","Hidradenitis Suppurativa","Prurigo Nodularis","Cutaneous Lupus",[175],"Inflammatory Skin Diseases","2025-07-17",{"date":178,"type":33},"2025-07-22",{"date":180,"type":33},"2023-05-01",{"date":182,"type":20},"2032-12-31",{"name":184,"class":40},"University Hospital Schleswig-Holstein",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":201,"leadSponsor":203,"locationsCount":41},"100574752","clinical-evaluation-and-study-of-the-efficacy-of-a-centella-asiatica-infused-facial-mask-on-discosmetic-dermatosis-100574752","NCT06763367","Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis","Inclusion Criteria:\n\n1. Meet mild to moderate rosacea, acne diagnostic criteria; Meet the diagnostic criteria for melasma;\n2. Over 18 years of age;\n3. Be able to follow the treatment rules of the study and be followed for 8 weeks;\n4. Informed consent; 5There were no significant cardiac, liver, kidney, gastrointestinal, neurological, psychiatric, or metabolic disorders\n\n6.No medication was used within 1 month\n\nExclusion Criteria:\n\n1. Currently pregnant, planning to become pregnant or breastfeeding;\n2. Documented hypersensitivity to any active ingredient or excipient included in the study drug, or a history of adverse reactions to cosmetic products;\n3. Participate in other clinical studies within 3 months before the start of the study;\n4. Frequent use of Chinese medicine, sleeping pills, sedatives, anti-anxiety drugs or potentially addictive substances;\n5. Present with concomitant skin conditions that may confuse the clinical assessment of rosacea, melasma, seborrheic dermatitis or pose a risk to participants, or have a history of severe skin conditions;\n6. Normal use of relevant treatment (including intense pulsed light, pulsed fuel laser, oral and topical tranexamic acid, oral tetracycline antibiotics, oral compound glycyrrhizin and other anti-inflammatory drugs)\n7. Patients with incomplete observation data, incomplete course of treatment and inability to take drugs as prescribed by doctors were removed",{"count":54,"type":20},[23],"The purpose of this study was to investigate the efficacy and safety of repairing facial mask containing Asiaticum asiatica in treating disjunctive skin diseases. A multi-center randomized double-blind self-half face control method was used. A computer-generated randomization method was used. Each cheek was randomly assigned to receive the snow glycoside mask and the control group.",[26,63,195,196],"Centella","Melasma","2025-01-02",{"date":199,"type":33},"2025-01-08",{"date":199,"type":20},{"date":202,"type":20},"2026-11-30",{"name":204,"class":40},"Nanjing First Hospital, Nanjing Medical University",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":89,"sex":16,"minAge":212,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":216,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":41},"100521628","effects-of-oral-supplement-containing-l-histidine-and-antioxidants-on-the-skin-barrier-function-and-systemic-inflammation-in-rosacea-100521628","NCT06072066","Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea","The Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea","Inclusion Criteria:\n\n* Males and females 30 to 70 years of age\n* The presence of mild to moderate rosacea (erythematotelangiectatic or papulopustular)\n* High sensitivity C-reactive protein (hs-CRP) that is greater than or equal to 1.0 mg\u002FL\n\nExclusion Criteria:\n\n* The presence of severe rosacea as noted by the investigator global assessment.\n* Those who are unwilling to discontinue oral supplementation, or supplement ingredients found in the study's oral product 1 month prior to enrollment.\n* Discontinuation of oral L-glutamine or L-glutamine containing supplement 1 month prior to enrollment\n* Those who are unwilling to discontinue topical benzoyl peroxide or retinoids for 2 weeks prior to enrollment.\n* Those who are unwilling to keep their facial regimen the same throughout the study.\n* Individuals who have been on an oral antibiotic within the previous one month.\n* Individuals who are pregnant or breastfeeding.\n* Individuals who have changed any of their hormonal based contraception or therapies within 3 months prior to joining the study.\n* Individuals on oral contraceptive pills or progesterone or estrogen containing therapies.\n* Use of isotretinoin within the three months prior to enrollment.\n* Individuals on finasteride or dutasteride\n* Current tobacco smoker, smoker within the past year, or greater than 5 pack-year tobacco smoking history.","30 Years","70 Years",{"count":215,"type":20},24,[23],"The purpose of this study is to evaluate how supplementation will alter the skin and the gut barrier and inflammation in those with rosacea.",[26,219],"Systemic Inflammation",[26,221,222],"L-Histidine","Antioxidants","2024-08-26",{"date":225,"type":33},"2024-08-27",{"date":227,"type":33},"2023-11-22",{"date":229,"type":20},"2024-12-31",{"name":231,"class":153},"Integrative Skin Science and Research",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":89,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":41},"100511654","the-use-of-image-based-computer-gradings-in-the-analysis-of-acne-rosacea-melasma-and-seborrheic-dermatitis-100511654","NCT05942248","The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis","Inclusion Criteria:\n\n* Adults with acne, rosacea, melasma or seborrheic dermatitis\n\nExclusion Criteria:\n\n* Prisoners\n* Adults unable to consent\n* Artificial facial markings on day of facial photography (such as piercings and tattoos) that may interfere with imaging in the opinion of the investigator",{"count":239,"type":20},150,[23],"The study is conducted to determine if image-based computer grading can of acne, melasma, rosacea and seborrheic dermatitis correlate well to expert based clinical severity grading.",[63,196,26,243],"Seborrheic Dermatitis",[245,246],"Artificial Intelligent","Skin",{"date":225,"type":33},{"date":249,"type":33},"2023-06-06",{"date":251,"type":20},"2025-02-28",{"name":231,"class":153}]